OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Investigational Drugs is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	106
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development	80
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	77
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	75
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	74
Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia	71
Theranostic strategies in sarcoma: preliminary clinical evidence	62
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development	61
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	56
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	53
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	53
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	51
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	44
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	43
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	41
Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials	41
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	37
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials	37
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	35
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease	33
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	32
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential	31
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	27
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	27
Investigational drugs for the treatment of dysmenorrhea	26

The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	26
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	26